| pioglitazone / Generic mfg. |
NCT01103414: Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients |
|
|
| Completed | 2b | 356 | US | Mitoglitazone, MSDC-0160, Pioglitazone, ACTOS, Placebo | Metabolic Solutions Development Company | Type 2 Diabetes | 11/11 | 12/11 | | |
NCT00760578: A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator |
|
|
| Completed | 2a | 86 | US | Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg | Metabolic Solutions Development Company | Type 2 Diabetes Mellitus | 01/09 | 02/09 | | |
NCT01280695: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients |
|
|
| Completed | 2a | 129 | US | Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone | Metabolic Solutions Development Company | Diabetes Mellitus, Type 2 | 06/11 | 06/11 | | |
NCT00676260: Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin |
|
|
| Completed | 2 | 29 | Europe | Pioglitazone, Actos, AD4833, Placebo | Takeda | Diabetes Mellitus | 08/04 | 08/04 | | |
NCT00762736: Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 704 | US, RoW | Pioglitazone and azilsartan, ACTOS®, AD4833, TAK-536, Pioglitazone | Takeda | Diabetes Mellitus | 10/05 | 10/05 | | |
NCT00229684: ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) |
|
|
| Terminated | 2 | 100 | US | Tesaglitazar, Galida, pioglitazone, Actos | AstraZeneca | Diabetes Mellitus, Type 2 | 06/06 | 06/06 | | |
| Completed | 2 | 448 | US, Canada, Europe, RoW | Pioglitazone, GW677954 | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 04/07 | 04/07 | | |
NCT00543959: Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005) |
|
|
| Terminated | 2 | 346 | US | MK0533, Comparator: Placebo (unspecified), Comparator: pioglitazone | Merck Sharp & Dohme LLC | Diabetes Mellitus Type 2 | 08/07 | 08/07 | | |
NCT00461058: A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure. |
|
|
| Completed | 2 | 14 | US, Europe, RoW | Actos, aleglitazar | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 12/07 | 12/07 | | |
| Completed | 2 | 334 | US, Europe, RoW | GSK189075, pioglitazone, Placebo | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 02/08 | 02/08 | | |
NCT00388518: A Study of Aleglitazar in Patients With Type 2 Diabetes |
|
|
| Completed | 2 | 332 | US, Europe, RoW | Actos, Placebo, aleglitazar | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 03/08 | 03/08 | | |
|
|
NCT00461006: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes. |
|
|
| Completed | 2 | 176 | US, RoW | Actos, aleglitazar | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 09/08 | 09/08 | | |
| Completed | 2 | 63 | Europe | Pioglitazone, ACTOS®, AD4833, Placebo | Takeda | Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes | 02/09 | 02/09 | | |
|
NCT00722917: Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus |
|
|
| Terminated | 2 | 323 | US | TAK-379, Actos, Pioglitazone, AD4833, Placebo | Takeda | Diabetes Mellitus | 04/09 | 04/09 | | |
NCT00631007: A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator |
|
|
| Completed | 2 | 367 | US, RoW | INT131 besylate, Pioglitazone HCl, Actos, Placebo | InteKrin Therapeutics, Inc. | Type 2 Diabetes Mellitus | 08/09 | 09/09 | | |
| Completed | 2 | 40 | Europe | Pioglitazone and insulin, ACTOS®, AD-4833, Insulin | Takeda | Diabetes Mellitus | 06/10 | 06/10 | | |
NCT00443755: Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance |
|
|
| Completed | 2 | 28 | US | metformin, Fortamet, Glucophage, Glucophage Extended Release (XR), Glumetza, Riomet, pioglitazone, Actos, Placebo | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Takeda Pharmaceuticals North America, Inc., National Center for Research Resources (NCRR) | Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome | 08/10 | 08/10 | | |
| Completed | 2 | 159 | Europe, RoW | Placebo, pioglitazone, CCX140-B | ChemoCentryx | Type 2 Diabetes Mellitus | 10/10 | 11/10 | | |
|
|
|
NCT01230749: A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 89 | US | JNJ-41443532, Pioglitazone 30 mg, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diabetes Mellitus, Type 2 | 06/11 | 06/11 | | |
NCT00633282: Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease |
|
|
| Completed | 2 | 184 | RoW | Life style intervention, calorie limited diet, aerobic exercise, pioglitazone, Actlns, PPAR agonist, Thiazolidinediones, insulin sensitizer, berberine, traditional Chinese medicine, herb | Xin Gao, Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Science and Technology Commission | Nonalcoholic Fatty Liver Disease | 08/11 | 08/11 | | |
| Completed | 2 | 302 | Europe, RoW | aleglitazar, pioglitazone | Hoffmann-La Roche | Diabetes Mellitus Type 2 | 07/12 | 07/12 | | |
|
|
NCT01396564: Pioglitazone and Metformin in Diabetic Children |
|
|
| Completed | 1/2 | 56 | RoW | Metformin, Recommended diet and 30 minutes of exercise daily, Pioglitazone | Coordinación de Investigación en Salud, Mexico | Type 2 Diabetes | 10/06 | 07/11 | | |
